Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroPharma Begins Phase 2 Study Of Subcutaneous Delivery Of Cinryze
Cinryze was approved by the FDA in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. ViroPharma said that the study will
Cinryze was approved by the FDA in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. ViroPharma said that the study will
As per the agreement, cancer vaccine experts at RUMC are expected to perform exploratory studies on Homspera relating to its adjuvant and immunomodulatory properties for potential application in
Shady Grove Fertility claimed that the new technology named ‘flash freezes’ increases chances of woman having her own biological children well past the age of peak fertility. Shady
Bosch Packaging Technology KHD 1000 allows for gloves to be tested for leaks using a validatable method before installation in the sterile area. The company claimed that by
The project is expected to expand Standard Process’ existing 260,000 square foot headquarters to accommodate additional processing capacity. The expansion is estimated to be completed by October 31,
HST Global said that with Benson’s assistance, it plans to license the ‘FIT’ protocol, as well as other pending protocols, to clinical treatment facilities in both Panama and
The rationale behind the closure is that the Chao Center has not been able to become self-sustaining during its five-year operation. According to Joseph Hornett, senior vice president,
Watson’s ANDA is for the generic equivalent of Teva’s Cenestin. The suit was filed on April 23, 2010, in the US District Court for the District of New
Through the center, PPD is expected to provide clinical monitoring services to global and local biopharmaceutical companies seeking to develop vaccines in China. Additionally, the center will help
DiabeCell is Living Cell Technologies’ treatment designed to normalise the lives of people with insulin-dependent diabetes. DiabeCell comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the